Trial Profile

A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms COMPLEMENT 2
Sponsors GlaxoSmithKline; GSK; Novartis

Most Recent Events

02 Jul 2019 Ther trial is completed at Romania (End Date: 25 Oct 2017), as per European Clinical Trials Database record.
04 Dec 2018 Results evaluating 5-year follow-up of overall survival (OS) and safety profile of the drugs presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
13 Dec 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com